Biostem Technologies Stock Forecast

Sell candidate since Jul 28, 2026 Loss -1.10%

The BioStem Technologies, Inc. stock price gained 3.57% on the last trading day (Friday, 31st Jul 2026), rising from $3.20 to $3.31. During the last trading day the stock fluctuated 23.40% from a day low at $3.12 to a day high of $3.85. The price has fallen in 6 of the last 10 days and is down by -12.09% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 68 thousand more shares were traded than the day before. In total, 90 thousand shares were bought and sold for approximately $298.34 thousand.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -19.66% during the next 3 months and, with a 90% probability hold a price between $2.24 and $3.35 at the end of this 3-month period.

BSEM Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, July 30, 2026, and so far it has risen 3.57%. Further rise is indicated until a new top pivot has been found. BioStem Technologies, Inc. has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The BioStem Technologies, Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.55 and $3.66. A break-up above any of these levels will issue buy signals. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

Support, Risk & Stop-loss for BioStem Technologies, Inc. stock

BioStem Technologies, Inc. finds support from accumulated volume at $3.29 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.730 between high and low, or 23.40%. For the last week, the stock has had daily average volatility of 13.32%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (BSEM) For The Upcoming Trading Day Of Monday 3rd

For the upcoming trading day on Monday, 3rd we expect BioStem Technologies, Inc. to open at $3.43, and during the day (based on 14 day Average True Range), to move between $3.13 and $3.49, which gives a possible trading interval of +/-$0.361 (+/-11.51%) up or down from last closing price. If BioStem Technologies, Inc. takes out the full calculated possible swing range there will be an estimated 11.51% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $3.29 (0.88%) than the resistance at $4.08 (23.11%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is BioStem Technologies, Inc. stock A Buy?

BioStem Technologies, Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.903 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on August 3, 2026 - $3.43 ( 3.44%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk